X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-19 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | S - Sale+OE | $216.91 | -4,300 | 12,946 | -25% | -$932,707 | |||||
| D | 2023-02-21 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | S - Sale+OE | $250.58 | -8,000 | 9,069 | -47% | -$2,004,675 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |